We Partner 4 Research

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Purpose

The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile and the post AMVAC TURBT findings, patients will be treated with active surveillance (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years, while preserving the bladder and thus quality-of-life for a proportion of patients.

Condition

Urothelial Carcinoma of the Bladder

Eligibility

Eligible Ages: Over 18 Years
Eligible Genders: All
Accepts Healthy Volunteers: No

Inclusion Criteria

Male or female patients ≥18 years. - Primary urothelial or predominantly urothelial carcinoma of the bladder. - Histologic evidence of muscularis propria invasion. - AJCC27 clinical stage T2-T4a . - No radiographic evidence of lymph node positivity (N0) or metastatic disease (M0). Clinical lymphadenopathy on staging CT greater than 1.5 cm in short axis must be biopsy proven negative. - ECOG performance status 0, 1, or 2. - Left ventricular ejection fraction ≥ 50% by MUGA or ECHO within 6 months of study entry. - Normal organ and bone marrow function as defined: Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional ULN Creatinine Creatinine Clearance ≥ 50 mL/min (calculated using the Cockroft-Gault formula or measured with 24 hour urine collection)

Exclusion Criteria

Any component of small cell histology. - Prior pelvic radiation therapy or patients who have undergone prior radiation to greater than or equal to 25% of the bone marrow within the past year are excluded due to risk of life threatening myelosuppression - Prior systemic chemotherapy; patients who have received any previous systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within 1 year of study entry are ineligible. - Prior or concurrent malignancy of any other site except for non-melanoma skin cancer, unless disease free interval ≥ 5 years. - Patients who have received experimental agents within 4 weeks of study entry. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to Methotrexate, Vinblastine, Adriamycin or Cisplatin or other agents used in the study - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (defined by current oral or intravenous antibiotic therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy. - Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with cytotoxic chemotherapy. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. - Patients with hydronephrosis that has not been addressed with an intervention such as placement of a stent. - Pregnancy & Women of Childbearing Potential

Study Design

Phase: Phase 2
Study Type: Interventional
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental CRT	Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then chemoradiation followed by TURBT#3	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Radiation: Intensity modulated radiation therapy (IMRT) 2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy Drug: 5-FU Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment Drug: Mitomycin C Intravenous on day 1 with radiation treatment
Experimental Surveillance	Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then active surveillance	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Experimental Intravesicle therapy	Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then intravesicle therapy followed by TURBT#3	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
Experimental Radical Cystectomy	Trimodality of Maximal TURBT#1 Followed by AMVAC and TURBT#2 and then cystectomy	Drug: Methotrexate Administered Day 1 of each 14 day cycle for 3 cycles Drug: Vinblastine Administered Day 1 of each 14 day cycle for 3 cycles Drug: Doxorubicin Administered Day 1 of each 14 day cycle for 3 cycles Drug: Cisplatin Administered Day 1 of each 14 day cycle for 3 cycles Procedure: Transurethral Resection of Bladder tumor Performed at before and after AMVAC and after chemoradiation and intravesicle therapy

More Details

Status: Active, not recruiting
Sponsor: Fox Chase Cancer Center

Study Contact

Detailed Description

This phase II trial studies how well maximal transurethral surgery (surgery performed with a special instrument inserted through the urethra) followed by accelerated methotrexate, vinblastine, doxorubicin hydrochloride, cisplatin, and radiation therapy work in treating patients with bladder cancer that has spread to the muscle. Drugs used in chemotherapy, such as methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Giving combination chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.